logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Patrick W Gray

This inventor holds 15 USPTO granted patents, plus 1 CIPO patent. Top assignees: Genentech, Inc., Other. Active years: 1987-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick W Gray. Retrieved from https://idiyas.com/inventor/patrick-w-gray-7q9800yy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 13

Forward Citations = 594(Granted Patents)


Location History:

  • Garnerville, NY (US) (1987)
  • San Francisco, CA (US) (1988 - 2002)

Company Filing History:

goldMedal13 out of 3,299 
 
Genentech, Inc.
 patents
silverMedal2 out of 834,513 
Other
 patents

Years Active: 1987-2002

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 6497871 - Recombiniant gamma interferons having enhanced stability and methods therefor (2002-12-24),
2. 6177543 - Recombinant lymphotoxin (2001-01-23),
3. 5824509 - Recombinant lymphotoxin cDNA and variants (1998-10-20),
4. 5690925 - Recombinant gamma interferons having enhanced stability and methods (1997-11-25),
5. 5683688 - Unglycosylated recombinant human lymphotoxin polypeptides and (1997-11-04),
6. 5595888 - Recombinant methods of making gamma interferon compositions (1997-01-21),
7. 5582824 - Recombinant DES-CYS-TYR-CYS human immune interferon (1996-12-10),
8. 5574137 - Recombinant gamma interferons having enhanced stability and methods (1996-11-12),
9. 5096705 - Human immune interferon (1992-03-17),
10. 4929554 - Human immune interferon (1990-05-29),
11. 4925793 - Human immune interferon (1990-05-15),
12. 4855238 - Recombinant gamma interferons having enhanced stability and methods (1989-08-08),
13. 4762791 - Human immune interferon (1988-08-09),
14. 4727138 - Human immune interferon (1988-02-23),
15. 4635938 - Board game (1987-01-13),

Title: The Innovative Contributions of Patrick W. Gray

Introduction

Patrick W. Gray is a prominent inventor based in San Francisco, California. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant proteins. With a total of 15 patents to his name, Gray's work has had a lasting impact on medical research and therapeutic applications.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Recombinant gamma interferons having enhanced stability and methods therefor" and "Recombinant lymphotoxin." These patents focus on biologically active lymphotoxin polypeptides synthesized in recombinant cell culture. The innovations include novel nucleic acids and vectors that enable the economical preparation of compositions containing uniform lymphotoxin polypeptides. Additionally, the lymphotoxins are purified to a specific activity of 2-10×10^6 units/mg of protein using a unique immobilized lymphotoxin-neutralizing monoclonal antibody.

Career Highlights

Throughout his career, Patrick W. Gray has worked with leading companies in the biotechnology sector, including Genentech, Inc. His expertise in recombinant technology has positioned him as a key figure in the development of therapeutic proteins. His contributions have not only advanced scientific understanding but have also paved the way for new treatment options.

Collaborations

Gray has collaborated with notable scientists in the field, including David V. Goeddel and Ernst H. Rinderknecht. These partnerships have fostered innovation and have been instrumental in the successful development of his patented technologies.

Conclusion

Patrick W. Gray's innovative work in biotechnology exemplifies the impact of dedicated inventors on the advancement of medical science. His patents and collaborations continue to influence the field, showcasing the importance of innovation in improving health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…